82 reports

  • RHEUMATOID ARTHRITIS

It causes chronic inflammation of any part or the entire gastrointestinal tract.

  • Arthritis
  • Cancer Immunotherapy
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Valeant manufactures and markets a wide range of branded generic pharmaceuticals, OTC products, and medical devices, catering to applications related to dermatology, eye health, aesthetics, consumer products, gastrointestinal health, oral health, neurology, and other therapeutic areas.

  • Arthritis
  • Allergan plc
  • Anika Therapeutics, Inc.
  • Sanofi S.A.
  • Seikagaku Corporation

Excluded from this report are Crohn' s disease and ulcerative colitis, as they fall under the gastrointestinal disorders therapy area.

  • Arthritis
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG
  • Market drivers

People with obesity, diabetes, hypertension, renal failure, cardiovascular diseases, gastrointestinal bleeding, depression, and trauma in joints due to repetitive movements are subject to high risk due to knee osteoarthritis.

  • Arthritis
  • Anika Therapeutics, Inc.
  • Ferring International Center S.A.
  • Sanofi S.A.
  • Seikagaku Corporation

Pharmaceutical: The Pharmaceutical segment includes products in areas, such as anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines.

  • Arthritis
  • United States
  • Anika Therapeutics, Inc.
  • Sanofi S.A.
  • Zimmer Biomet Holdings, Inc.
  • 18.2 Market Share Analysis 2014

NSAIDs adversely affect the gastrointestinal, renal, and cardiovascular systems when used for over the long term.

  • Arthritis
  • Abbott Laboratories, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.

Rheumatoid arthritis

4546 5000 3864
  • PREVALENCE OF SELECTED CO-MORBIDITIES REPORTED IN THE INTERNATIONAL COMORA STUDY, BY REGION,...
  • RHEUMATOID ARTHRITIS PATIENTS RECEIVING TRADITIONAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS,...

Side effects include gastrointestinal bleeding, and increased blood pressure particularly in hypertensive patients (van Laar, 2012).

  • Arthritis
  • Europe
  • Japan
  • Pfizer Inc.
  • Roche Group
  • Opportunities for research in osteoarthritis
  • Vendor landscape

DONULIDE IS NOT RECOMMENDED FOR PATIENTS WITH GASTROINTESTINAL BLEEDING, ULCER, AND HYPERSENSITIVITY.

  • Arthritis
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

  • Arthritis
  • China
  • Demand
  • Novartis AG
  • Pfizer Inc.
  • Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Preclinical
  • 7 Appendix

Its main reported adverse effects are related to the gastrointestinal tract and the nervous system.

  • Arthritis
  • Therapy
  • World
  • Market Size
  • Remicade group

REFERENCE CODE GDHCER##-## | PUBLICATION DATE JANUARY 2017 RHEUMATOID ARTHRITIS - EPIDEMIOLOGY FORECAST TO 2025 Executive Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity.

  • Arthritis
  • Australia
  • Japan
  • United States
  • Forecast

gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

  • Arthritis
  • China
  • Bayer AG
  • Novartis AG
  • Pfizer Inc.

Appendix ##. ## ABBREVIATIONS ##MM: ##EU: ##MM: ACR: ANA: BMS: BRIC: BSR: CAGR: CBC: CCP: CDC: CRP: csDMARD: DAS##: DMARD: DNA: ESR: EULAR: FDA: FLS: GI: GP: fibroblast-like synoviocytes gastrointestinal general practitioner ## major markets (US, France, Germany, Italy, Spain, UK, Japan, Austral

  • Arthritis
  • United States
  • Forecast
  • Amgen Inc.
  • Pfizer Inc.
  • RHEUMATOID ARTHRITIS THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY PFIZER...
  • RHEUMATOID ARTHRITIS THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY ASTRAZENECA...

gastrointestinal disease.

  • Arthritis
  • World
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

gastrointestinal granulocyte macrophage colony-stimulating factor general practitioner GlaxoSmithKline Health Action International Health Assessment Questionnaire Haute Autorité de Santé hydrochloroquine interleukin interleukin-## receptor idiopathic pulmonary fibrosis Immune Response BioPha

  • Arthritis
  • United States
  • World
  • Forecast
  • Toyama Chemical Co., Ltd.

gastrointestinal general practitioner C-reactive protein India) Appendix GSK: HAQ: HAS: HCQ: IL: IL-##R: IPF: IV: J& J: JAK: JPMA: KOL: LEF: MRI: MTX: NHI: NICE: NSAID: OUS: PAS: PCP: PGA: GlaxoSmithKline Health Assessment Questionnaire Haute Autorité de Santé hydrochloroquine interleukin

  • Arthritis
  • United States
  • World
  • Forecast
  • Astellas Pharma Inc.

Masitinib was subsequently rejected by the EMA in March 2014 for malignant gastrointestinal stromal tumors.

  • Arthritis
  • Pathology
  • Therapy
  • Forecast
  • AstraZeneca PLC

gastrointestinal general practitioner GlaxoSmithKline Health Assessment Questionnaire Haute Autorité de Santé hydrochloroquine immunoglobulin G## interleukin idiopathic pulmonary fibrosis intravenous Johnson & Johnson janus kinase Japan Pharmaceutical Manufacturers Association key opinio

  • Arthritis
  • Pathology
  • Therapy
  • United States
  • Forecast

gastrointestinal general practitioner GlaxoSmithKline Health Action International Health Assessment Questionnaire Haute Autorité de Santé hydrochloroquine interleukin interleukin-## receptor idiopathic pulmonary fibrosis Immune Response BioPharma intravenous Johnson & Johnson janus kinas

  • Arthritis
  • Therapy
  • United States
  • Forecast
  • Roche Group

gastrointestinal C-reactive protein conventional synthetic disease-modifying anti-rheumatic drugs Appendix GP: GSK: HAQ: HAS: HCQ: IL: IL-##R: IPF: IRBP: IV: J& J: JAK: KOL: LEF: mAb: MRI: MTX: NHI: NICE: NSAID: OUS: PAS: PCP: outside the US Patient Activity Scale primary care physician m

  • Arthritis
  • Forecast
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

gastrointestinal C-reactive protein conventional synthetic disease-modifying anti-rheumatic drugs Appendix GP: GSK: GVHD: HAQ: HAS: HCQ: IL: IL-##R: IPF: IRBP: IV: J& J: JAK: JPMA: KOL: LEF: mAb: MRI: MTX: NHI: NICE: NSAID: OUS: outside the US GM-CSF: granulocyte macrophage colony-stimula

  • Arthritis
  • Pathology
  • Therapy
  • Forecast
  • AstraZeneca PLC

gastrointestinal methotrexate National Health Insurance Appendix PAS: PCP: PGA: PMPRB: QOL: R& D: RA: RANKL: RF: SC: SDAI: sDMARD: SSc: SYK: TB: TNF: TNFα: Treg cells: tsDMARD: Patient Activity Scale primary care physician Patient Global Assessment Patented Medicine Prices Review Board q

  • Arthritis
  • Therapy
  • Forecast
  • AbbVie Inc.
  • Galapagos NV

gastrointestinal FDA: FLS: GI: GM-CSF: GP: GSK: HAQ: HAS: HCQ: IL: IL-##R: IPF: IRBP: IV: J& J: JAK: KOL: LEF: mAb: MRI: MTX: NHI: NICE: NSAID: Food and Drug Administration fibroblast-like synoviocytes granulocyte macrophage colony-stimulating factor general practitioner GlaxoSmithKline H

  • Arthritis
  • Therapy
  • Forecast
  • AstraZeneca PLC
  • MedImmune, LLC

gastrointestinal Appendix NICE: NSAID: OUS: PAS: PCP: PGA: PMPRB: QOL: R& D: RA: RANKL: RF: SC: SDAI: sDMARD: SSc: SYK: TB: National Institute for Health and Care Excellence nonsteroidal anti-inflammatory drug outside the US Patient Activity Scale primary care physician Patient Global As

  • Arthritis
  • Therapy
  • Forecast
  • AstraZeneca PLC
  • Janssen Biotech, Inc.

gastrointestinal intravenous Johnson & Johnson janus kinase methotrexate National Health Insurance Appendix OUS: PAS: PCP: PGA: PMPRB: QOL: R& D: RA: RANKL: RF: SC: SDAI: sDMARD: SSc: SYK: TB: TNF: TNFα: Treg cells: tsDMARD: outside the US Patient Activity Scale primary care physicia

  • Arthritis
  • Pathology
  • Therapy
  • Forecast
  • Novartis AG

gastrointestinal granulocyte macrophage colony-stimulating factor general practitioner GlaxoSmithKline Health Assessment Questionnaire Haute Autorité de Santé hydrochloroquine interleukin interleukin-## receptor idiopathic pulmonary fibrosis Immune Response BioPharma intravenous Johnson &

  • Arthritis
  • Pathology
  • Therapy
  • Forecast
  • AstraZeneca PLC

gastrointestinal India) Appendix GP: GSK: HAQ: HAS: HCQ: HDL-C: IL: IL-##R: IPF: IRBP: IV: J& J: JAK: JPMA: KOL: LDL-C: LEF: mAb: MRI: mTSS: MTX: NHI: NICE: intravenous Johnson & Johnson janus kinase granulocyte macrophage colony-stimulating factor general practitioner GlaxoSmithKline

  • Arthritis
  • Therapy
  • Forecast
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.

gastrointestinal methotrexate National Health Insurance outside the US Appendix PAS: PCP: PGA: PMPRB: QOL: R& D: RA: RANKL: RF: SC: SDAI: sDMARD: SSc: SYK: TB: TNF: TNFα: Treg cells: tsDMARD: Patient Activity Scale primary care physician Patient Global Assessment Patented Medicine Prices

  • Arthritis
  • Therapy
  • Forecast
  • AbbVie Inc.
  • AstraZeneca PLC

gastrointestinal C-reactive protein conventional synthetic disease-modifying anti-rheumatic drugs India) Appendix GP: GSK: HAQ: HAS: HCQ: IgG##: IL: IL-##R: IPF: IRBP: IV: J& J: JAK: JPMA: KOL: LEF: mAb: MRI: MTX: NHI: NICE: NSAID: OUS: outside the US GM-CSF: granulocyte macrophage colony-

  • Arthritis
  • Forecast
  • Amgen Inc.
  • AstraZeneca PLC
  • Sankyo Co., Ltd.

COHERUS BIOSCIENCES INC (CHRS) - PHARMACEUTICALS & HEALTHCARE - DEALS AND ALLIANCES PROFILE Coherus BioSciences Inc (Coherus BioSciences) formerly known as BioGenerics Inc is a biosimilar platform company that develops and commercializes biosimilar drugs.

  • Arthritis
  • Pharmaceutical
  • United States
  • Company
  • Coherus BioSciences, Inc.